China Pharma Holdings, Inc. — Q1 2012 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2012. The company develops, manufactures and sells generic and branded pharmaceuticals in China; all operations are in the PRC. Its 20 commercialized products are sold through 16 sales offices and approximately 1,800 independent distributors. Results for the quarter are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $16.09 million | $18.12 million; down 11% |
| Gross profit / margin | $5.30 million / 33.0% | $6.87 million / 37.9% |
| Operating income / margin | $3.41 million / 21.2% | $5.34 million / 29.5%; operating income down 36% |
| Net income / diluted EPS | $2.81 million / $0.06 | $5.10 million / $0.12; net income down 45% |
| Operating cash flow | $0.12 million | $1.39 million |
| Cash and cash equivalents | $3.32 million at March 31 | $4.05 million at December 31, 2011 |
| Current assets / current liabilities | $117.12 million / $17.27 million | Approximate current ratio: 6.8x |
| Short-term notes payable | $3.96 million | No additional availability under the credit line |
Cash declined $0.73 million during the quarter. Investing activities used $0.80 million, mainly for advances on drug formulas; there were no financing cash flows in Q1 2012. Receivables were $73.55 million, up from $69.70 million at year-end, and inventory was $34.32 million, up from $30.38 million. The company reported $62.3 million of receivables more than 90 days old. Management said $3.66 million of cash and banker’s acceptances was considered indefinitely reinvested in its PRC subsidiary and not expected to be available to the parent or shareholders.
Material changes and management commentary
- Management attributed the revenue decline primarily to disruption and pricing changes associated with China’s healthcare reform. It said pricing pressure affects products across the portfolio and expects pressure to persist, with potential ongoing gross-margin effects.
- Gross margin fell to 33.0% from 37.9%. Management cited pricing pressure; gross profit declined 23%. Selling expenses rose 48% to $0.89 million, primarily due to sales-team labor costs. General and administrative expenses declined 26% to $0.68 million.
- Q1 2011 net income included a $0.68 million derivative gain; there was no derivative gain in Q1 2012. The lower revenue and margins, higher operating expenses, and absence of that prior-year gain contributed to the net-income decline.
- Product revenue was led by Anti-Viro/Infection & Respiratory at $6.8 million and CNS Cerebral & Cardio Vascular at $4.8 million. The “Other” category fell 37% to $2.0 million, with Vitamin B6 cited as a major contributor.
- Management said new products, including Candesartan and Rosuvastatin, could support margins after launch. Candesartan was awaiting final SFDA production approval; Rosuvastatin’s production approval application had been submitted. The company reported a combination antibiotic in Phase II trials and a coronary heart disease product in Phase III, with trial completion anticipated by year-end 2012.
Risks, contingencies and unusual items
- Receivables are a significant collection and cash-flow risk: $62.3 million was more than 90 days old, and 23.2% of receivables were aged 365–720 days. The allowance for doubtful accounts was $3.88 million. Management said it had not written off customer receivables, but collection timing was long.
- The $3.96 million revolving bank loan bears 7.54% interest, is due within one year of each advance, and is secured by certain land-use rights and buildings. The company had no remaining availability under the line at March 31.
- Operations and revenue are concentrated in China and denominated in RMB. Government controls on currency conversion and remittance may restrict transfers to the U.S. parent; PRC political, regulatory, economic and currency risks could adversely affect results.
- Advances for purchases of intangible assets were $37.21 million. SFDA approval processes typically take two to five years; the filing notes approval is not assured, although contracts provide refund or substitution rights if approval is denied or a laboratory breaches contract.
- The company reported no material commitments outside ordinary-course expenditures and no off-balance-sheet arrangements. It stated that the prior-year material weakness concerning accounting for intangible-asset amortization had been remediated through personnel training.
- Subsequent events: on April 28, 2012, the company cancelled 185,000 vested CFO options in exchange for 100,000 common shares and expected to record $55,775 in stock-compensation expense. On May 9, the CEO was appointed interim CFO.
Most important facts for investors to verify
- Whether the company can collect its large, aged receivables and convert earnings into operating cash flow.
- Whether healthcare-reform pricing pressure continues to reduce revenue, product margins or distributor activity.
- Timing and outcome of SFDA approvals and clinical trials, and whether pipeline launches deliver the margin support management expects.
- Access to PRC subsidiary cash, including the practical impact of reinvestment and currency-remittance restrictions.
- The filing’s inconsistent description of the Q1 2012 bad-debt amount: the financial statements and allowance roll-forward show a $320,098 expense, while one MD&A sentence calls the same amount a “benefit.”
- Product-category disclosure inconsistencies: the table shows Anti-Viro/Infection & Respiratory revenue down 4% and Digestive revenue down 2%, while the related narrative gives different percentage changes.